CD3-specific antibodies: a portal to the treatment of autoimmunity.
about
Apotopes and the biliary specificity of primary biliary cirrhosisRecent advances in understanding Type 1 DiabetesConcordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsImmune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experienceInduction of immunological tolerance by oral anti-CD3Immunotherapy in autoimmune type 1 diabetesDetermining disease intervention strategies using spatially resolved simulationsMechanisms of Oral ToleranceGenetics, pathogenesis and clinical interventions in type 1 diabetesCD3 antibody and IL-2 complex combination therapy inhibits atherosclerosis by augmenting a regulatory immune response.Cell separation: Terminology and practical considerations.Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays.Human antigen-specific regulatory T cells generated by T cell receptor gene transfer.Therapeutic potential of TGF-β-induced CD4(+) Foxp3(+) regulatory T cells in autoimmune diseases.An allosteric site in the T-cell receptor Cβ domain plays a critical signalling role.Haptoglobin as an early serum biomarker of virus-induced autoimmune type 1 diabetes in biobreeding diabetes resistant and LEW1.WR1 ratsLethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome.NOD2 regulates CXCR3-dependent CD8+ T cell accumulation in intestinal tissues with acute injury.Mouse Models for Type 1 Diabetes.Immune tolerance induction by integrating innate and adaptive immune regulators.Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseasesIL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cellsNew insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppressionControl of TH17 cells occurs in the small intestine.Beta cell antigens in type 1 diabetes: triggers in pathogenesis and therapeutic targets.Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials.Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.The role of dendritic cells in tissue-specific autoimmunity.Anti-CD3 antibody ameliorates experimental autoimmune uveitis by inducing both IL-10 and TGF-β dependent regulatory T cells.The SCHOOL of nature: III. From mechanistic understanding to novel therapiesAnti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells.Piecing together the family portrait of TCR-CD3 complexes.Molecular architecture of the αβ T cell receptor-CD3 complex.New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunityChallenges in the pursuit of immune tolerance.Normalization of obesity-associated insulin resistance through immunotherapyStrategies to stabilize compact folding and minimize aggregation of antibody-based fragmentsTherapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetesPopulation dynamics of islet-infiltrating cells in autoimmune diabetes.Targeting natural killer cell reactivity by employing antibody to NKp46: implications for type 1 diabetes.
P2860
Q24646460-11727811-DA4A-4F26-9299-BC5C13FD2A61Q26766139-FD02B41F-DB69-49B8-9C13-F93B8943029FQ26830569-DF41AA35-40CA-45AC-A314-24AA50C504AEQ26850621-A7F2A8C0-2623-4FF9-BA6F-05DF6F63249AQ26863556-AF02F721-19EB-4322-B96C-865712A80FD1Q27025619-F0215808-1F9B-47EB-8185-AE96765CF08DQ27301846-0B627F18-C6C7-4661-B6E9-E9E2249B4015Q28082715-55B8100D-973A-4D7F-8CAF-3EC074A7E63CQ28281029-E593BC7F-DFEF-4F2C-95E2-E49DE3E07183Q30426856-2CE0FD0A-5B64-4F44-A454-6DD1ABA90D59Q30458000-DE645710-6E96-4825-B1A9-E910A0A0B69FQ33507170-EBDCD807-E417-4E82-973D-31901E45DCE6Q33644234-27970692-DDE4-4826-A6CE-2D0BA16A231AQ33684806-C9968960-D4E9-48CF-8BD4-EED5F6D8A286Q33716306-4803009A-AAFA-4997-A8FE-F6D5F98AF068Q33727660-D72A56D9-8D27-4812-BFB7-FB1148AAEE72Q33743988-A7F2EFC4-4C8B-4009-A0B2-F38FD986ADB5Q33782590-A4F33FF5-638B-4E26-953E-2E5EBDF8A05FQ33794336-F6043E48-11C1-4A9B-85C4-95ADA0888D33Q33907609-611FC1AF-FF3D-47A9-93B4-F66010A85E0DQ34071942-FF749608-50B0-4713-83DB-354E21B68692Q34096577-4EFC693F-DF44-48F4-AF3F-1C1ACBF56B3BQ34175958-61A8EEAE-2E9C-4173-91F0-543B33EB073BQ34201256-A5443304-4833-41C9-904E-35E4B6ECDCD7Q34309199-86A8CA99-AAAD-460D-B3ED-5EE831E2E47EQ34318993-BA3DAE47-4B3C-468C-89F1-1362F8A0D886Q34375578-D3B4187B-B79E-4AFE-A323-B8B7FB2AA8AFQ34422017-58D16D46-3682-4F9F-9D4A-03D9439541ECQ34613306-E69A28B9-5945-4F3C-A9EE-03B69E6DD45BQ34619705-CB3FFA85-5ADB-45FD-A67C-66B7E6379DA0Q34630923-8F3E34EA-35B5-41DC-973E-4B8CBA248232Q34643623-F7A17908-5F12-40C3-B024-75563943708DQ34708948-47C4B009-3BA3-405D-82F3-CCAB42DD9955Q34831889-0FADCA60-E7DD-45A9-9CB1-0FC55A06E4CCQ34974448-62F8EEED-2F1F-4E9B-8636-3E708CA1A293Q34994222-C2712688-F0D5-455B-A60F-16C16537B63EQ35018813-B24C88CC-D95B-48F6-9BDE-E7D8DF5FA771Q35035148-6FF0E5A6-B207-4926-94C6-293EC13212C2Q35062855-D6C741B4-AAC9-4F5D-A6F0-C59EEF536B13Q35125149-0C742882-0142-4613-99A7-1C8DF6F8DF2A
P2860
CD3-specific antibodies: a portal to the treatment of autoimmunity.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
CD3-specific antibodies: a portal to the treatment of autoimmunity.
@ast
CD3-specific antibodies: a portal to the treatment of autoimmunity.
@en
CD3-specific antibodies: a portal to the treatment of autoimmunity.
@nl
type
label
CD3-specific antibodies: a portal to the treatment of autoimmunity.
@ast
CD3-specific antibodies: a portal to the treatment of autoimmunity.
@en
CD3-specific antibodies: a portal to the treatment of autoimmunity.
@nl
prefLabel
CD3-specific antibodies: a portal to the treatment of autoimmunity.
@ast
CD3-specific antibodies: a portal to the treatment of autoimmunity.
@en
CD3-specific antibodies: a portal to the treatment of autoimmunity.
@nl
P356
P1476
CD3-specific antibodies: a portal to the treatment of autoimmunity.
@en
P2093
Jeffrey A Bluestone
P304
P356
10.1038/NRI2134
P577
2007-07-20T00:00:00Z